Kamran Alam - 02 Feb 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: Chief Financial Officer
Signature: /s/ Kamran Alam
Issuer symbol: TSHA
Transactions as of: 02 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 06 Feb 2023, 20:12:21 UTC
Previous filing: 24 Aug 2022
Next filing: 10 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TSHA	Common Stock	Award		+18,691	+7%		284,812	02 Feb 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+37,384		$0.000000	37,384	02 Feb 2023	Common Stock	37,384	$1.18	Direct	F3
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+149,900		$0.000000	149,900	02 Feb 2023	Common Stock	149,900	$1.18	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. 12,461 RSUs shall vest 25% on each of February 2, 2024, February 2, 2025, February 2, 2026 and February 2, 2027. The remaining RSUs, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
F2	Each RSU represents a contingent right to receive one share the Issuer's common stock.
F3	24,923 shares underlying the option shall vest 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter. The remaining shares underlying the option, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.
F4	25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.